Cargando…

Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein

The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the first Middle East respiratory syndrome (MERS) outbreaks. MERS-CoV causes an acute lower-respiratory infection in humans, with a fatality rate of ~35.5%. Currently, there are no registered vaccines or means...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ozharovskaia, T. A., Zubkova, O. V., Dolzhikova, I. V., Gromova, A. S., Grousova, D. M., Tukhvatulin, A. I., Popova, O., Shcheblyakov, D. V., Scherbinin, D. N., Dzharullaeva, A. S., Erokhova, A. S., Shmarov, M. M., Loginova, S. Y., Borisevich, S. V., Naroditsky, B. S., Logunov, D. Y., Gintsburg, A. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	A.I. Gordeyev 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475872/ https://www.ncbi.nlm.nih.gov/pubmed/31024747

Ejemplares similares

Preclinical Studies of Immunogenity, Protectivity, and Safety of the Combined Vector Vaccine for Prevention of the Middle East Respiratory Syndrome
por: Dolzhikova, I. V., et al.
Publicado: (2020)

Toll-Like Receptors (TLRs): The Role in Tumor Progression
por: Shcheblyakov, D.V., et al.
Publicado: (2010)

Adjuvantation of an Influenza Hemagglutinin Antigen with TLR4 and NOD2 Agonists Encapsulated in Poly(D,L-Lactide-Co-Glycolide) Nanoparticles Enhances Immunogenicity and Protection against Lethal Influenza Virus Infection in Mice
por: Tukhvatulin, Amir, et al.
Publicado: (2020)

Virus-Vectored Ebola Vaccines
por: Dolzhikova, I.V., et al.
Publicado: (2017)

Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses
por: Tukhvatulin, Amir I., et al.
Publicado: (2016)

NOD1/2 and the C-Type Lectin Receptors Dectin-1 and Mincle Synergistically Enhance Proinflammatory Reactions Both In Vitro and In Vivo
por: Tukhvatulin, Amir I, et al.
Publicado: (2020)

Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis
por: Burmistrova, Daria A., et al.
Publicado: (2016)

An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults
por: Tukhvatulin, Amir I., et al.
Publicado: (2021)

Stimulation of Dectin-1 and Dectin-2 during Parenteral Immunization, but Not Mincle, Induces Secretory IgA in Intestinal Mucosa
por: Dzharullaeva, Alina S., et al.
Publicado: (2018)

Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study
por: Tukhvatulin, Amir I., et al.
Publicado: (2023)

Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection
por: Voronina, Daria V., et al.
Publicado: (2022)

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
por: Logunov, Denis Y, et al.
Publicado: (2020)

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
por: Logunov, Denis Y, et al.
Publicado: (2021)

Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia
por: Dolzhikova, I. V., et al.
Publicado: (2017)

Triggering of Toll-like Receptor-2 in Mouse Myelomonocytic Leukaemia Cells WEHI-3B Leads to the Suppression of Apoptosis and Promotes Tumor Progression in Vivo
por: Shcheblyakov, D.V., et al.
Publicado: (2011)

Nanobodies Are Potential Therapeutic Agents for the Ebola Virus Infection
por: Esmagambetov, I. B., et al.
Publicado: (2021)

Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates
por: Tukhvatulin, Amir I., et al.
Publicado: (2022)

Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals
por: Lapa, Daniele, et al.
Publicado: (2022)

Chlamydial Type III Secretion System Needle Protein Induces Protective Immunity against Chlamydia muridarum Intravaginal Infection
por: Koroleva, Ekaterina A., et al.
Publicado: (2017)

A In Vitro and In Vivo Study of the Ability of NOD1 Ligands to Activate the Transcriptional Factor NF-kB
por: Tukhvatulin, A.I., et al.
Publicado: (2011)

rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19
por: Esmagambetov, Ilias B., et al.
Publicado: (2023)

Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice
por: Godakova, Svetlana A., et al.
Publicado: (2019)

Construction of a pIX-modified Adenovirus Vector Able to Effectively Bind to Nanoantibodies for Targeting
por: Garas, M. N., et al.
Publicado: (2014)

Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus
por: Gushchin, Vladimir A., et al.
Publicado: (2022)

Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial – Authors' reply
por: Logunov, Denis Y, et al.
Publicado: (2021)

An Efficient Method for the Delivery of the Interleukin-2 Gene to Human Hematopoietic Cells using the  Fiber-Modified Recombinant Adenovirus
por: Rogozhin, V.N., et al.
Publicado: (2011)

Safety and efficacy of the Russian COVID-19 vaccine: more information needed – Authors’ reply
por: Logunov, Denis Y, et al.
Publicado: (2020)

Regulation of the Target Protein (Transgene) Expression in the Adenovirus Vector Using Agonists of Toll-Like Receptors
por: Bagaev, A. V., et al.
Publicado: (2014)

Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
por: Fomina, Daria S., et al.
Publicado: (2023)

rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis
por: Derkaev, Artem A., et al.
Publicado: (2022)

Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern
por: Favorskaya, Irina A., et al.
Publicado: (2022)

Induction of a Protective Heterosubtypic Immune Response Against the Influenza Virus by using Recombinant Adenoviral Vectors Expressing Hemagglutinin of the Influenza H5 Virus
por: Shmarov, M.M., et al.
Publicado: (2010)

Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants
por: Gushchin, Vladimir A., et al.
Publicado: (2021)

Effective Genetic Expression of Nanoantibodies by Recombinant Adenoviral Vector in vitro
por: Gribova, I.Yu., et al.
Publicado: (2011)

Non-neutralizing Antibodies Directed at Conservative Influenza Antigens
por: Sedova, E. S., et al.
Publicado: (2019)

Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A
por: Panova, Eugenia A., et al.
Publicado: (2023)

Protective Immune Response against Bacillus anthracis Induced by Intranasal Introduction of a Recombinant Adenovirus Expressing the Protective Antigen Fused to the Fc-fragment of IgG2a
por: Shcherbinin, D. N., et al.
Publicado: (2014)

Non-thermal Plasma Causes p53-Dependent Apoptosis in Human Colon Carcinoma Cells
por: Tuhvatulin, A.I., et al.
Publicado: (2012)

Recombinant Influenza Vaccines
por: Sedova, E.S., et al.
Publicado: (2012)

Development of Neutralizing Nanobodies to the Hemagglutinin Stem Domain of Influenza A Viruses
por: Voronina, D. V., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r2lpe21f3at9k80lt2i0qsaj8v